

CHAPTER ONE: INTRODUCTION.....	1
OBJECTIVES AND GOAL OF THE STUDY	1
REASONS FOR DOING THE STUDY	1
SCOPE OF THE STUDY	2
TARGETED AUDIENCE	3
METHODOLOGY	4
ANALYST CREDENTIALS.....	5
RELATED REPORTS.....	5
BCC ONLINE SERVICES.....	5
DISCLAIMER	6
 CHAPTER TWO: SUMMARY.....	 7
<i>SUMMARY TABLE MARKETS FOR IMMUNOAGENTS, PROBES AND</i>	
<i>MOLECULAR DIAGNOSTICS, THROUGH 2016 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE MARKETS FOR IMMUNOAGENTS, PROBES</i>	
<i>AND MOLECULAR DIAGNOSTICS, 2009-2016 (\$ MILLIONS)</i>	8
SUMMARY (CONTINUED)	9
 CHAPTER THREE: TECHNOLOGY OVERVIEW.....	 10
IMMUNOASSAY TECHNOLOGY.....	10
QUALITATIVE AND QUANTITATIVE IMMUNOASSAYS	10
APPLICATIONS FOR IMMUNOASSAY TECHNIQUES	11
COMPARISON OF IMMUNOASSAYS WITH CONVENTIONAL	
METHODS	11
HIGH SENSITIVITY	11
HIGH ACCURACY.....	12
SPEED	12
COST FACTORS	12
METHODS OF IMMUNOASSAYS.....	12
IMMUNOPRECIPITATION	13
PARTICLE IMMUNOASSAYS.....	13
RADIOIMMUNOASSAY (RIA).....	14
Immunoradiometric Assays	14
IMMUNONEPHELOMETRY	15
ENZYME IMMUNOASSAY (EIA).....	15
Enzyme-Linked Immunosorbent Assays (ELISA)	16
FLUORESCENT IMMUNOASSAY (FIA).....	16
Fluorescence Polarization (FP): A Variation of FIA.....	16
CHEMILUMINESCENT ASSAY (CLIA)	17
IMMUNOASSAY TECHNIQUES	17
MONOCLONAL-POLYCLONAL (MOAB-POAB) SANDWICH	
IMMUNOASSAY	17
COMPETITIVE INHIBITION IMMUNOASSAY.....	18
ANTIGEN-DOWN IMMUNOASSAY	18

RAPID IMMUNOASSAYS.....	18
GENE PROBE TECHNOLOGY (NUCLEIC ACID ASSAYS)	19
DNA PROBES UTILIZED FOR ASSESSING TUMOR GENES IN PATIENT SPECIMENS.....	19
<i>TABLE 1 COMMONLY USED CHEMILUMINESCENT COMPOUNDS</i>	20
GENE PROBES	20
MOLECULAR BEACONS.....	21
<i>TABLE 2 COMMON MOLECULAR BEACON AND QUENCHER COMBINATIONS</i>	22
DETECTION OF BACTERIAL CONTAMINATION IN FOODS.....	22
CHIP-BASED NUCLEIC ACID ASSAY	23
REPORTER GENE ASSAY	23
<i>TABLE 3 FDA APPROVED NUCLEIC ACID TEST USING DNA PROBE TECHNOLOGIES</i>	24
<i>TABLE 3 (CONTINUED)</i>	25
<i>TABLE 3 (CONTINUED)</i>	26
<i>TABLE 3 (CONTINUED)</i>	27
CHAPTER FOUR: OVERVIEW OF PROBES AND RELATED CHEMICALS.....	28
RADIOACTIVE COMPOUNDS	28
<i>TABLE 4 PROPERTIES OF RADIOACTIVE ISOTOPES USED IN RADIOACTIVE LABELED PROBES</i>	28
ENZYMES/ENZYME SUBSTRATES	29
FLUORESCENT COMPOUNDS	29
CHEMILUMINESCENCE COMPOUNDS.....	30
GENE PROBES	30
CONSTRUCTION OF GENE PROBES.....	30
PROBE LABELING	31
RADIOACTIVE PROBES USED IN DIAGNOSTIC IMAGING	31
<i>TABLE 5 RADIONUCLIDES COMMONLY USED FOR DIAGNOSTIC IMAGING</i>	32
<i>TABLE 6 USE OF RADIOACTIVE PROBES – THYROID IMAGING</i>	33
<i>TABLE 7 ADDITIONAL USE OF ISOTOPES IN THYROID SCANNING</i>	34
<i>TABLE 8 RADIO-LABELED ANTIBODIES FOR DIAGNOSIS OF SPECIFIC CANCERS</i>	34
<i>TABLE 8 (CONTINUED)</i>	35
<i>TABLE 9 USE OF RADIOACTIVE PROBES IN DIAGNOSIS OF THYROIDISM</i>	35
<i>TABLE 10 USE OF RADIOACTIVE PROBES – RADIO- CARDIOGRAPHY</i>	36
<i>TABLE 11 USE OF RADIOACTIVE PROBES – TUMOR IMAGING</i>	36
<i>TABLE 12 USE OF RADIOACTIVE PROBES – CANCER TREATMENT</i>	37
<i>TABLE 13 USE OF RADIOACTIVE PROBES – DETERMINATION OF CIRCULATION RED CELL MASS/PLASMA VOLUME</i>	37

<i>TABLE 14 USE OF RADIOACTIVE PROBES – DETERMINATION OF BLOOD FLOW</i>	38
<i>TABLE 15 USE OF RADIOACTIVE PROBES – STOMACH IMAGING</i>	38
<i>TABLE 16 USE OF RADIOACTIVE PROBES – TREATMENT OF LEUKEMIAS</i>	38
<i>TABLE 17 USE OF RADIOACTIVE PROBES – STUDY OF GASTROINTESTINAL PROTEIN LOSS</i>	39
<i>TABLE 18 USE OF RADIOACTIVE PROBES – SCANNING LUNGS/BRAIN</i>	39
<i>TABLE 19 USE OF RADIOACTIVE PROBES – MYOCARDIAL STUDIES</i>	39
<i>TABLE 19 (CONTINUED)</i>	40
<i>TABLE 20 USE OF RADIOACTIVE PROBES – HEART IMAGING</i>	40
<i>TABLE 21 USE OF RADIOACTIVE PROBES – CEREBRAL PERFUSION IMAGING</i>	41
<i>TABLE 22 USE OF RADIOACTIVE PROBES – BONE IMAGING</i>	41
<i>TABLE 23 USE OF RADIOACTIVE PROBES – LUNG IMAGING</i>	41
<i>TABLE 23 (CONTINUED)</i>	42
HEPATOBIILIARY IMAGING.....	42
RETICULOENDOTHELIAL SYSTEM.....	42
<i>TABLE 24 USE OF RADIOACTIVE PROBES – RENAL IMAGING</i>	43
<i>TABLE 25 USE OF RADIOACTIVE PROBES – MALIGNANT AND INFLAMMATORY REGIONS</i>	43
<i>TABLE 26 USE OF RADIOACTIVE PROBES – AUTORADIOGRAPHY</i>	43
TRENDS IN RADIOLABELED ANTIBODY THERAPY.....	44
RADIOPHARMACEUTICAL MARKET.....	44
ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) ASSAY PROCEDURES.....	45
<i>TABLE 27 COMMON TYPES OF ELISA ASSAY</i>	45
A CAPTURE EIA IS DESIGNED TO DETECT A SPECIFIC TYPE OF ANTIBODY, SUCH AS IGG OR IGM.....	46
<i>TABLE 28 ENZYMES AND SUBSTRATES USED IN ELISA ASSAYS</i>	47
FLUORESCENCE COMPOUNDS.....	47
<i>TABLE 29 COMMONLY USED FLUOROPHORES IN FIA</i>	47
<i>TABLE 29 (CONTINUED)</i>	48
<i>TABLE 30 FLUOROPHORES AND THEIR APPLICATIONS</i>	48
<i>TABLE 30 (CONTINUED)</i>	49
<i>TABLE 31 FLUOROPHORES AND THEIR APPLICATIONS</i>	49
FLUORESCENT DOT IMAGING.....	49
MOLECULAR IMAGING AND OPTICAL IMAGING.....	50
OPTICAL IMAGING.....	50
<i>TABLE 32 RADIO-PROBES USED IN MOLECULAR IMAGING</i>	51
CHEMILUMINESCENT COMPOUNDS.....	52
<i>TABLE 33 COMMONLY USED CHEMILUMINESCENT COMPOUNDS</i>	52

<i>TABLE 34 BLOTTING METHODS DEVELOPED FOR BIOMOLECULAR SPECIES</i>	53
FLOW CYTOMETRY.....	54
CLINICAL APPLICATIONS OF FLOW CYTOMETER	55
<i>TABLE 35 FLUOROCHROME DYES USED IN MOLECULAR DIAGNOSTICS AND MOLECULAR PROBES</i>	56
<i>TABLE 35 (CONTINUED)</i>	57
<i>TABLE 35 (CONTINUED)</i>	58
<i>TABLE 35 (CONTINUED)</i>	59

CHAPTER FIVE: MARKETS FOR IMMUNOAGENTS, AND MOLECULAR DIAGNOSTICS BY APPLICATION SECTORS	60
CHANGES IN THE GLOBAL MARKETS FOR IMMUNOGENIC PROBES	60
<i>TABLE 36 LIST OF FDA-APPROVED DRUGS THAT HAVE BIOMARKER INFORMATION INCLUDED IN THEIR LABELING</i>	61
<i>TABLE 36 (CONTINUED)</i>	62
<i>TABLE 36 (CONTINUED)</i>	63
<i>TABLE 36 (CONTINUED)</i>	64
<i>TABLE 36 (CONTINUED)</i>	65
<i>TABLE 36 (CONTINUED)</i>	66
CHANGES IN THE GLOBAL MARKETS ... (CONTINUED)	67
<i>TABLE 37 GLOBAL MARKET FOR IMMUNOAGENTS, PROBES, AND MOLECULAR DIAGNOSTICS BY APPLICATION SECTORS, THROUGH 2016 (\$ MILLIONS)</i>	68
<i>TABLE 38 DIAGNOSTIC CATEGORIES FOR FAILED DRUG CLINICAL TRIALS IN PERIOD 2008-2016</i>	69
<i>TABLE 39 GLOBAL MARKET BY MATERIALS FOR PROBES IN IMMUNOASSAYS, THROUGH 2016 (\$ MILLIONS)</i>	70
<i>TABLE 40 GLOBAL MARKET BY MATERIALS FOR PROBES IN IMMUNOASSAYS INCLUDING MOLECULAR ANTIBODY THERAPY, THROUGH 2016 (\$ MILLIONS)</i>	71
<i>TABLE 41 REGIONAL SHARE OF THE MARKET FOR IMMUNOAGENTS, PROBES, AND MOLECULAR DIAGNOSTICS, THROUGH 2016 (\$ MILLIONS)</i>	71
POINT-OF-CARE TESTS.....	72
REQUIREMENTS FOR POC DEVICES	72
Requirements for POC Devices (Continued)	73
<i>TABLE 42 FDA CRITERIA FOR CATEGORIZING POTENTIAL POC TEST</i>	74
<i>TABLE 43 TYPES OF POC TESTS WITH AUTOMATIC WAIVED STATUS</i>	75
<i>TABLE 44 GLOBAL REVENUES FROM POC TESTING, THROUGH 2016 (\$ MILLIONS)</i>	76

<i>TABLE 45 GLOBAL MARKET FOR IN VITRO DIAGNOSTICS POC TESTS BY APPLICATION SECTORS, THROUGH 2016 (\$ MILLIONS).....</i>	<i>77</i>
<i>TABLE 46 GLOBAL DISTRIBUTION OF IN VITRO DIAGNOSTICS POC TESTS BY REGION, 2010 (\$ MILLIONS).....</i>	<i>78</i>
MOLECULAR DIAGNOSTICS TESTS.....	78
Molecular Diagnostics tests (Continued).....	79
MOLECULAR DIAGNOSTICS REVENUE PROJECTIONS.....	80
<i>TABLE 47 GLOBAL REVENUES FROM MOLECULAR DIAGNOSTICS TESTS, THROUGH 2016 (\$ MILLIONS).....</i>	<i>80</i>
FDA-APPROVED MDX TESTS.....	80
<i>TABLE 48 CURRENT FDA APPROVED MOLECULAR DIAGNOSTICS TESTS.....</i>	<i>81</i>
<i>TABLE 48 (CONTINUED).....</i>	<i>82</i>
<i>TABLE 48 (CONTINUED).....</i>	<i>83</i>
<i>TABLE 48 (CONTINUED).....</i>	<i>84</i>
<i>TABLE 48 (CONTINUED).....</i>	<i>85</i>
<i>TABLE 48 (CONTINUED).....</i>	<i>86</i>
<i>TABLE 48 (CONTINUED).....</i>	<i>87</i>
<i>TABLE 49 MOLECULAR DIAGNOSTICS SYSTEMS CURRENT IN COMMERCE 2011.....</i>	<i>87</i>
<i>TABLE 49 (CONTINUED).....</i>	<i>88</i>
<i>TABLE 49 (CONTINUED).....</i>	<i>89</i>
<i>TABLE 49 (CONTINUED).....</i>	<i>90</i>
INFECTIOUS DISEASE TESTING.....	90
<i>TABLE 50 FDA-APPROVED INFECTIOUS DISEASE TESTS.....</i>	<i>91</i>
<i>TABLE 50 (CONTINUED).....</i>	<i>92</i>
<i>TABLE 50 (CONTINUED).....</i>	<i>93</i>
<i>TABLE 50 (CONTINUED).....</i>	<i>94</i>
<i>TABLE 50 (CONTINUED).....</i>	<i>95</i>
NEXT-GENERATION MOLECULAR DIAGNOSTICS.....	96
U.S. PATENTS FOR MOLECULAR DIAGNOSTICS.....	96
<i>TABLE 51 NUMBER OF U.S. PATENTS ISSUED FOR MOLECULAR DIAGNOSTICS DURING THE PERIOD, THROUGH 2010.....</i>	<i>97</i>
<i>TABLE 51 (CONTINUED).....</i>	<i>98</i>
<i>TABLE 52 NUMBER OF U.S. PATENTS ISSUED TO UNIVERSITIES DURING THE PERIOD, THROUGH 2010.....</i>	<i>99</i>
THE RISE OF COMPANION DIAGNOSTICS.....	99
The Rise of Companion Diagnostics (Continued).....	100
The Rise of Companion Diagnostics (Continued).....	101
BLOOD BANK IMMUNE TESTING.....	102
FOOD TESTING IMMUNOASSAYS.....	103
FORENSIC, BIOTERRORISM, AND PATERNITY MARKETS.....	104
FORENSICS.....	104
PATERNITY AND MATERNITY TESTING.....	104

BIOTERRORISM	105
MERGERS AND ACQUISITIONS.....	106
<i>TABLE 53 PHARMACEUTICAL AND BIOTECHNOLOGY MERGERS AND ACQUISITIONS IN 2010.....</i>	<i>106</i>
<i>TABLE 53 (CONTINUED).....</i>	<i>107</i>
<i>TABLE 54 MAJOR ACQUISITIONS IN BIOPHARMACOLOGY/BIOTECHNOLOGY IN 2009.....</i>	<i>107</i>
<i>TABLE 55 MAJOR MERGER AND ACQUISITION ACTIVITY IN BIOTECH INDUSTRY DURING THE PERIOD 2005 THROUGH 2008.....</i>	<i>108</i>
WORLDWIDE IMMUNOASSAY AND MOLECULAR DIAGNOSTICS ACTIVITY	109
<i>TABLE 56 DISTRIBUTION OF GLOBAL REVENUES FOR IMMUNOASSAYS, GENE PROBES, AND MOLECULAR DIAGNOSTICS, 2010.....</i>	<i>110</i>
JAPAN	110
CHINA	110
RUSSIA.....	111
BRAZIL.....	112
CHAPTER SIX: COMPANY PROFILES.....	113
MARKET SHARE OF MAJOR COMPANIES.....	113
<i>TABLE 57 MARKET SHARE OF MAJOR COMPANIES IN THE IMMUNOASSAY AND MOLECULAR DIAGNOSTICS AREAS, 2010.....</i>	<i>113</i>
ABBOTT LABORATORIES.....	114
COMPANY OVERVIEW.....	114
PRODUCTS AND SERVICES.....	114
IMMUNOASSAY	114
<i>TABLE 58 REPRESENTATIVE IMMUNOASSAY PRODUCTS AND AUTOMATED SYSTEMS (ARCHITECT SERIES) FOR THEIR ANALYSIS.....</i>	<i>115</i>
GENE PROBE AND MOLECULAR DIAGNOSTICS	115
AFFYMETRIX.....	116
COMPANY OVERVIEW.....	116
PRODUCTS AND SERVICES.....	116
BECKMAN-COULTER.....	117
COMPANY OVERVIEW.....	117
PRODUCTS AND SERVICES.....	117
BIOMÉRIEUX.....	118
COMPANY OVERVIEW.....	118
PRODUCTS AND SERVICES.....	118
<i>TABLE 59 BIOMÉRIEUX BIOMARKERS.....</i>	<i>118</i>
BIO-RAD LABORATORIES.....	119
COMPANY OVERVIEW.....	119
PRODUCTS AND SERVICES.....	120
GE HEALTHCARE LIFE SCIENCES.....	120

COMPANY OVERVIEW.....	120
PRODUCTS AND SERVICES.....	120
GENENTECH, INC.	121
COMPANY OVERVIEW.....	121
PRODUCTS AND SERVICES.....	121
<i>TABLE 60 GENENTECH PRODUCTS IN PRODUCTION.....</i>	<i>122</i>
GEN-PROBE INCORPORATED.....	123
COMPANY OVERVIEW.....	123
PRODUCTS AND SERVICES.....	123
<i>TABLE 61 GEN-PROBE STANDARDIZED ANTIBODIES</i>	<i>124</i>
LIFE TECHNOLOGIES	124
COMPANY OVERVIEW.....	124
PRODUCTS AND SERVICES.....	125
<i>TABLE 62 LIFE TECHNOLOGIES' CELL-LIGHT MOLECULAR</i>	
<i> SIGNALING DYES.....</i>	<i>125</i>
<i>TABLE 62 (CONTINUED).....</i>	<i>126</i>
MILLIPORE CORPORATION (MERCK KGAA)	126
COMPANY OVERVIEW.....	126
PRODUCTS AND SERVICES.....	127
QIAGEN, INC.	127
COMPANY OVERVIEW.....	127
PRODUCTS AND SERVICES.....	128
ROCHE DIAGNOSTICS.....	128
COMPANY OVERVIEW.....	128
PRODUCTS AND SERVICES.....	129
<i>TABLE 63 ROCHE DIAGNOSTIC TESTS.....</i>	<i>129</i>
SIGMA-ALDRICH, USA.....	130
COMPANY OVERVIEW.....	130
PRODUCTS AND SERVICE.....	130
<i>TABLE 64 MAJOR PRODUCT OFFERINGS OF SIGMA-ALDRICH.....</i>	<i>131</i>
THERMO FISHER LIFE SCIENCES.....	131
COMPANY OVERVIEW.....	131
PRODUCTS AND SERVICES.....	132
<i>TABLE 65 CUSTOMIZED ANTIBODY PRODUCTION PROCESS OF</i>	
<i> THERMO FISHER LIFE SCIENCES.....</i>	<i>132</i>